> Cell and Gene Therapy Solutions > Response Profiling
Sensitivity, accuracy and speed are critical factors in successfully monitoring the safety and efficacy of cell and gene therapies post-treatment. ProteinSimple platforms and provide simple yet sophisticated solutions for biomarker and cell type profiling and characterization that minimize the sample volume needed for analysis.
Profiling Immune Cell Populations
High-resolution view of immune cell composition and function in the TME
The complexity and heterogeneity of immune cell signatures, combined with a finite sample, make the tumor microenvironment (TME) a particularly difficult area of investigation. In the Application note, Wes and Milo Synergize to Profile Immune Cell Populations in the Tumor Microenvironment, see how these two systems team up to deliver both the type of immune cell populations that are present in your sample, and what percentage of cells in that sample make up a specific immune cell subtype. You’ll also get these population-level and single-cell-level results much faster than other methods while conserving your precious sample.
CAR T Cell Biomarkers
Monitor for Cytokine Release Syndrome post CAR T therapy
Early identification of Cytokine Release Syndrome (CRS), the most common adverse reaction to T-cell infusion, requires rapid and accurate evaluation of the immune response to effectively correlate biomarker data with clinical evidence. In the poster Characterizing CAR T Cell Therapy Biomarkers Through Multianalyte Analysis, see how Ella let researchers at Moffit Cancer Center quantitate biomarkers in CAR T donor serum to generate unique immune response profiles. Ella’s Simple Plex assays let you accurately quantify and capture more datapoints per sample. Get results for up to 8 biomarkers per sample in 75 minutes, while using just 25 µL of precious sample. Find out how our wide range of validated Simple Plex assays can be used in your immune reactivity and inflammation research.
Solutions for Monitoring Cell Therapies In Patient Biopsies
In-situ hybridization with RNAscope™ assays from ACD enables specific detection of viral-vector based cell therapies in intact human tumor biopsies. Explore how these assays are used to monitor cell therapies in post-treatment patient biopsies and in preclinical animal models for safety and efficacy. View ACD’s solutions for Cell Therapy here at acdbio.com/science/applications/research-areas/cell-therapy.